Screener
Pacific Biosciences of California PACB Business Segments — Settlement charges
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept pacb:SettlementCharges.
The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001299130-26-000122
| (In thousands, except per share amounts) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 23,022 | 22,529 | 42,630 | 51,582 |
| Sales, general and administrative | 33,393 | 36,175 | 64,546 | 76,343 |
| Impairment charges | — | — | — | 15,000 |
| Settlement charges | — | — | 15,400 | — |
| Gain on disposal of assets | — | — | (45,796) | — |
| Amortization of acquired intangible assets | 833 | 833 | 1,666 | 362,875 |
| Change in fair value of contingent consideration | — | — | — | (18,700) |
| Total operating expense | 57,248 | 59,537 | 78,446 | 487,100 |
Item 1. Financial Statements (unaudited):
FAQ
- What is Pacific Biosciences of California's business segments — settlement charges?
- Pacific Biosciences of California (PACB) reported business segments — settlement charges of $0 in Q2 2026.
- What does business segments — settlement charges mean?
- These are costs associated with the resolution of legal disputes, regulatory fines, or contractual settlements. Tracking these charges is essential for understanding non-recurring operational risks and potential liabilities that impact the bottom line.
Ask your AI about Pacific Biosciences of California's business segments — settlement charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude